Mylan (MYL) to Post FY2017 Earnings of $4.55 Per Share, Leerink Swann Forecasts
Mylan (NASDAQ:MYL) – Research analysts at Leerink Swann issued their FY2017 earnings per share (EPS) estimates for shares of Mylan in a research note issued to investors on Tuesday. Leerink Swann analyst A. Fadia expects that the company will post earnings per share of $4.55 for the year. Leerink Swann has a “Market Perform” rating and a $44.00 price target on the stock. Leerink Swann also issued estimates for Mylan’s Q4 2017 earnings at $1.42 EPS, FY2018 earnings at $5.35 EPS, FY2019 earnings at $5.70 EPS, FY2020 earnings at $6.25 EPS and FY2021 earnings at $6.89 EPS.
A number of other equities analysts have also recently commented on MYL. Citigroup reiterated a “buy” rating and set a $58.00 price target (up previously from $48.00) on shares of Mylan in a report on Thursday. BMO Capital Markets reiterated a “buy” rating and set a $45.00 price target on shares of Mylan in a report on Friday, September 29th. ValuEngine upgraded Mylan from a “hold” rating to a “buy” rating in a report on Monday, October 2nd. Instinet reiterated a “buy” rating and set a $37.00 price target on shares of Mylan in a report on Thursday, October 5th. Finally, Cowen reiterated a “market perform” rating and set a $36.00 price target (up previously from $30.00) on shares of Mylan in a report on Thursday, October 5th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company. Mylan has a consensus rating of “Buy” and a consensus target price of $43.20.
Mylan (NASDAQ:MYL) last posted its quarterly earnings results on Monday, November 6th. The company reported $1.10 EPS for the quarter, missing analysts’ consensus estimates of $1.20 by ($0.10). Mylan had a return on equity of 20.63% and a net margin of 7.28%. The business had revenue of $2.99 billion for the quarter, compared to the consensus estimate of $3.09 billion. During the same quarter in the previous year, the business posted $1.38 EPS. The company’s revenue for the quarter was down 2.3% on a year-over-year basis.
Several large investors have recently modified their holdings of the company. Meeder Asset Management Inc. boosted its stake in shares of Mylan by 76.9% in the third quarter. Meeder Asset Management Inc. now owns 3,393 shares of the company’s stock valued at $106,000 after buying an additional 1,475 shares during the period. BT Investment Management Ltd bought a new stake in shares of Mylan in the third quarter valued at approximately $142,000. Doliver Capital Advisors LP bought a new stake in shares of Mylan in the second quarter valued at approximately $201,000. Sheaff Brock Investment Advisors LLC bought a new stake in shares of Mylan in the second quarter valued at approximately $210,000. Finally, Loews Corp bought a new stake in shares of Mylan in the second quarter valued at approximately $223,000. Institutional investors own 74.90% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This article was first published by American Banking News and is owned by of American Banking News. If you are reading this article on another website, it was stolen and reposted in violation of United States & international copyright legislation. The correct version of this article can be read at https://www.americanbankingnews.com/2018/01/05/mylan-myl-to-post-fy2017-earnings-of-4-55-per-share-leerink-swann-forecasts.html.
Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.
Receive News & Ratings for Mylan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan and related companies with MarketBeat.com's FREE daily email newsletter.